Joris Silon

Patients

In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease.

Views & Analysis

AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.

News

Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.